Alnylam Pharmaceuticals | ALNY - 销售收入

金融业

USD

USD 5.13B

现金及等价物

USD 1.71B

USD 211.12M

USD 4.22B

USD 1.35B

USD 1.28B

USD 137.59M

USD 145.22M

2.23K

EPS每股收益

USD 1.99

股本和储备

USD 1.08B

USD 825.01M

债务利息支出

USD 69.29M

USD 26.63M

USD 2.48B

USD 37.39B

USD 205.99M

USD 898.54M

USD 137.59M

普通股股本

USD 133.44M

80.04

USD 221.65M

USD 1.17B

销售和管理费用

USD 282.51M

USD 200.15M

贸易债权人

USD 126.63M

应收帐款人

USD 883.96M

	销售	更改		日
Acadia Pharmaceuticals	USD 268.06M		15.94M	2026-03
Agios Pharmaceuticals	USD 18.8M		1.17M	2026-03
Alnylam Pharmaceuticals	USD 1.17B		70M	2026-03
Amgen	USD 8.62B		1.28B	2026-03
Arrowhead Research	USD 73.74M		190.29M	2026-03
BioCryst Pharmaceuticals	USD 406.56M		247.16M	2025-12
BioMarin Pharmaceutical	USD 766M		109M	2026-03
Incyte	USD 1.27B		240M	2026-03
Ionis Pharmaceuticals	USD 246M		43M	2026-03
Moderna	USD 389M		289M	2026-03
Neurocrine Biosciences	USD 811M		5.5M	2026-03
Novartis	USD 13.11B		750M	2026-03
PTC Therapeutics	USD 273M		108.3M	2026-03
Regeneron Pharmaceuticals	USD 3.6B		280M	2026-03
Sangamo BioSciences	USD 356K		125K	2024-06
Sanofi	EUR 12.14B		65M	2026-03
Sarepta Therapeutics	USD 730.8M		287.9M	2026-03
Takeda	JPY 1.09T		100B	2026-03
Tectonic Therapeutic	USD 0		0	2024-12
Ultragenyx Pharmaceutical	USD 136M		71M	2026-03
Vertex Pharmaceuticals	USD 2.99B		200M	2026-03
Xencor	USD 4.51M		23.73M	2026-03